Clinical observation on the adjuvant treatment of 33 cases of refractory mycoplasma pneumoniae pneumonia in children with phlegm heat injury syndrome with Huotan Wan(豁痰丸)
Objective To observe the clinical efficacy of Huotan Wan(豁痰丸)as an adjunctive treatment for children with refractory mycoplasma pneumoniae pneumonia(RMPP)with phlegm heat injury syndrome.Meth-ods 65 children with RMPP phlegm heat injury syndrome who were treated in the pediatric inpatient department of Liuyang Traditional Chinese Medicine Hospital from August 2021 to September 2022 were selected.They were ran-domly divided into a control group of 32 cases and a treatment group of 33 cases using a random number table meth-od.The control group was treated with conventional Western medicine and azithromycin,while the treatment group was treated with Huotan Wan on the basis of the control group's treatment method.Both groups were treated with one week as a course of treatment.After two courses,clinical efficacy was calculated,and clinical symptoms,disap-pearance time of lung rales and hospitalization time,and changes in inflammatory indicators were compared.Results The recovery rate of the treatment group was 75.76％(25/33),which was significantly higher than that of the control group at 50.00％(16/32).The difference between the two groups was statistically significant(P＜0.05).The time for fever relief,disappearance of cough and lung rales,and hospital stay in the treatment group were significant-ly shorter than those in the control group.The difference between the two groups was statistically significant(P＜0.05).Before treatment,there was no statistically significant difference(P＞0.05)in the main symptom,secondary symptom scores,and total scores between the two groups,indicating comparability.After treatment,the scores of two groups significantly decreased,and compared with the same group before treatment,the difference was statistically significant(P＜0.05),and the treatment group showed a more significant decrease(P＜0.05).There was no statisti-cally significant difference(P＞0.05)in the levels of inflammatory factors such as white blood cell count(WBC),C-reactive protein(CRP),lactate dehydrogenase(LDH),and erythrocyte sedimentation rate(ESR)between the two groups before treatment,indicating comparability.After treatment,the values of indicators significantly decreased in both groups,and the difference was statistically significant(P＜0.05)compared to before treatment in the same group,with the treatment group showing a more significant decrease(P＜0.05).Conclusion Huotan Wan has a definite therapeutic effect in assisting the treatment of RMPP with phlegm heat injury syndrome in children.lt can significantly reduce the traditional Chinese medicine syndrome score of children,shorten the time for disappearance of lung rales and hospitalization,reduce inflammatory reactions,and is worthy of clinical promotion and application.
NETL
NSTL
万方数据
